Effect of Coenzyme Q10 Supplementation on Simvastatin-Induced Myalgia

American Journal of Cardiology

Volumn 100, Issue 9, 2007, Pages 1400-1403

  Young, Joanna M ^a   Florkowski, Christopher M ^a,b   Molyneux, Sarah L ^b   McEwan, Roberta G ^a   Frampton, Christopher M ^c   George, Peter M ^b   Scott, Russell S ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SIMVASTATIN; UBIDECARENONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG TOLERANCE; FEMALE; HUMAN; MALE; MONOTHERAPY; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; VISUAL ANALOG SCALE;

COENZYMES; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCULAR DISEASES; PILOT PROJECTS; SIMVASTATIN; UBIQUINONE; VITAMINS;

EID: 35348863203     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.06.030     Document Type: Article

References (19)

1. Stalenhoef A.F., Mol M.J., and Stuyt P.M. Efficacy and tolerability of simvastatin (MK-733). Am J Med 87 (1989) 39S-43S
2. London S.F., Gross K.F., and Ringel S.P. Cholesterol-lowering agent myopathy (CLAM). Neurology 41 (1991) 1159-1160
3. Scott R.S., Lintott C.J., and Wilson M.J. Simvastatin and side effects. N Z Med J 104 (1991) 493-495
4. Grundy S.M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319 (1998) 24-33
5. Ravnskov U., Rosch P.J., Sutter M.C., and Houston M.C. Should we lower cholesterol as much as possible?. BMJ 332 (2006) 1330-1332
6. La Rosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., and Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
7. Rauchova H., Drahota Z., and Lenaz G. Function of coenzyme Q in the cell: some biochemical and physiological properties. Physiol Res 44 (1995) 209-216
8. Elmberger P.G., Kalen A., Lund E., Reihner E., Eriksson M., Berglund L., Angelin B., and Dallner G. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. J Lipid Res 32 (1991) 935-940
9. Ghirlanda G., Oradei A., Manto A., Lippa S., Uccioli L., Caputo S., Greco A.V., and Littarru G.P. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 33 (1993) 226-229
10. Bargossi A.M., Battino M., Gaddi A., Fiorella P.L., Grossi G., Barozzi G., Di Giulio R., Descovich G., Sassi S., Genova M.L., and Lenaz G. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Int J Clin Lab Res 24 (1994) 171-176
11. Laaksonen R., Ojala J.P., Tikkanen M.J., and Himberg J.J. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 46 (1994) 313-317
12. Kelly P., Vasu S., Getato M., McNurlan M., and Lawson W.E. Coenzyme Q10 improves myopathic pain in statin treated patients. J Am Coll Cardiolol 45 suppl (2005) 3A
13. Molyneux S., Florkowski C., Lever M., and George P. The bioavailability of coenzyme Q10 supplements available in New Zealand differs markedly. N Z Med J 117 (2004) U1108
14. Tang P.H., Miles M.V., DeGrauw A., Hershey A., and Pesce A. HPLC analysis of reduced and oxidized coenzyme Q(10) in human plasma. Clin Chem 47 (2001) 256-265
15. Marbach E.P., and Weil M.H. Rapid enzymatic measurement of blood lactate and pyruvate. Use and significance of metaphosphoric acid as a common precipitant. Clin Chem 13 (1967) 314-325
16. Landstad B.J., Schuldt K., Ekholm J., Broman L., and Bergroth A. Women at work despite ill health: diagnoses and pain before and after personnel support. A prospective study of hospital cleaners/home-help personnel with comparison groups. J Rehabil Med 33 (2001) 216-224
17. Laaksonen R., Jokelainen K., Laakso J., Sahi T., Harkonen M., Tikkanen M.J., and Himberg J.J. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 77 (1996) 851-854
18. Heart Protection Collaborative Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
19. Flint O.P., Masters B.A., Gregg R.E., and Durham S.K. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol 145 (1997) 99-110